Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.

The present invention relates to methods for obtaining skeletal muscle derived cells (SMDC), and the use of SMDCs in a method of preventing and/or treating neuromyopathies and/or myopathies, wherein the neuromyopathy and/or myopathy is incontinence, in particular a urinary and/or an anal or fecal incontinence.

The present disclosure is directed to a feeder-cell free methods of producing an expanded natural killer (NK) cell preparation. This method comprises providing a starting preparation of NK cells and treating the starting preparation with a natural killer cell p30-related protein (NKp30) modulating agent alone or with other expansion agents as described herein. The method further involves culturing the treated preparation under conditions effective to expand the starting preparation of NK cells to produce an expanded NK cell preparation. Other aspects of the disclosure related to therapeutic preparations of NK cells produced in accordance with the methods described herein.

The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.

Disclosed herein are cells that are immunoinhibitory cell, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the cell. In certain embodiments, the immunoinhibitory cell is a regulatory T cell. In another aspect, provided herein is a regulatory T cell that recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response. The cells can be sensitized to an antigen that is the target of a pathologic immune response associated with an immune-mediated disorder. Additionally provided are methods of using such cells to treat an immune-mediated disorder in a subject in need thereof.

The present invention provides compositions and methods for activation and expansion of T cells using a biocompatible solid substrate with tunable rigidity. Rigidity of a substrate is an important parameter that can be used to control the overall expansion and differentiation of T cells.

The present invention relates to a method of expanding and generating a population of cytokine-induced killer (CIK) cells from peripheral blood mononuclear cells comprising steps of a) separating the mononuclear cells from the peripheral blood; b) transferring the separated mononuclear cells into a culture medium; c) adding cytokines into the culture medium to induce expansion and generation of the CIK cells; and d) obtaining the expanded and generated population of CIK cells.

A kit for use in adding to a cultural medium for culturing natural killer (NK) cells includes a B unit including a basic solution including IL-2, L-glutamine dissolved in a cell culture medium, a C1 unit including of a cytokine 1 solution including IL-12 and IL-18 dissolved in the basic solution, a C2 unit including of a cytokine 2 solution including IL-15 dissolved in the basic solution, an A1 unit including of an antibody 1 solution including an anti-CD16 antibody and an anti-CD56 antibody dissolved in the basic solution, an A2 unit including of an antibody 2 solution including the antibody 1 solution and the basic solution in a volume ratio of 1:6-10, and a D unit including of an antibody-cytokine mixed solution including an anti-CD3 antibody dissolved in the cytokine 1 solution.

The present disclosure relates to compositions and methods for enhancing cell response and/or expanding chimeric antigen receptor (CAR) cells and/or maintenance in vivo and/or in vitro. In embodiments, the method comprises obtaining CAR T cells comprising a CAR comprising a binding domain that binds a solid tumor antigen, a transmembrane domain, and an intracellular domain; and contacting the CART cells with white blood cells and a bispecific antibody, such as a Bispecific T cell engager (BiTE®), thereby activating the CAR T cells, wherein the level of activation of the CAR T cells is higher than the level of activation of CAR T ells that are contacted with B cells without the bispecific antibody. The bispecific antibody comprises a first binding domain binding CD3 and a second binding domain binding CD19, CD20, CD22, or BCMA.

A feeder cell for culturing natural killer (NK) cells, genetically engineered to express membrane bound interleukin-18 (mbIL-18), membrane bound interleukin-21 (mbIL-21), and/or OX40L. A method of proliferating NK cells, including: obtaining a blood sample containing a population of NK cells; and contacting at least a part of the population of NK cells with a genetically engineered cell, where the genetically engineered cell is genetically engineered to express mbIL-18, mbIL-21, and/or OX40L.